Efficacy and safety of zolbetuximab for first-line treatment of advanced Claudin 18. 2-positive gastric or gastro-esophageal junction adenocarcinoma: a systematic review and meta-analysis of randomized controlled trials

OBJECTIVE: Zolbetuximab is a “first-in-class” chimeric lgG1 monoclonal antibody targeting Claudin18.2 (CLDN 18.2). In recent years, several important trials have been published showing that zolbetuximab is associated with improved prognosis in patients with advanced gastric or gastro-esophageal junc...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Zhanpeng, Liu, Liwen, Li, Wenxia, Lai, Huiqin, Li, Luzhen, Wu, Jiaming, Zhang, Huatang, Fang, Cantu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598679/
https://www.ncbi.nlm.nih.gov/pubmed/37886169
http://dx.doi.org/10.3389/fonc.2023.1258347

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598679/
https://www.ncbi.nlm.nih.gov/pubmed/37886169
http://dx.doi.org/10.3389/fonc.2023.1258347

Ejemplares similares